Key result
P2X7 receptor antagonism reduces atrial fibrillation susceptibility and structural remodeling in preclinical models.
Why the study?
Atrial fibrillation is driven by inflammatory activation and oxidative stress, but the precise molecular links remain unclear.
Does P2X7 receptor antagonism prevent atrial remodeling and atrial fibrillation susceptibility in preclinical murine models?
Does P2X7 receptor antagonism prevent atrial remodeling and atrial fibrillation susceptibility in preclinical murine models?
p-value: p=<0.05
P2X7 receptors promote atrial fibrillation vulnerability and remodeling via a ROS-mediated MAPK signaling axis, identifying a potential novel therapeutic target for AF.
Atrial fibrillation (AF), the most common clinical arrhythmia, is driven by inflammatory activation and oxidative stress, though precise molecular links remain unclear. This study identifies the P2X7 receptor as a key upstream regulator orchestrating proarrhythmic atrial remodeling through reactive oxygen species (ROS)-mediated mitogen-activated protein kinase (MAPK) signaling. Transcriptomic analysis of rapid-paced cardiomyocytes revealed P2X7 upregulation and MAPK pathway enrichment. Functional validation demonstrated that P2X7 activation promotes ROS accumulation, MAPK phosphorylation (p-ERK, p-p38, and p-JNK), and pro-inflammatory cytokine release (IL-6 and IL-1β), culminating in action potential shortening and calcium handling dysfunction. Critically, both P2X7 inhibition (A-438079) and ROS scavenging (NAC) attenuated this signaling axis. In vivo, P2X7 antagonism reduced AF susceptibility, improved conduction heterogeneity, and ameliorated structural and autonomic remodeling. These results establish the P2X7-ROS-MAPK axis as a central mechanism in AF vulnerability and highlight its therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Atrial fibrillation (n=18). P2X7 receptor antagonist A-438079 vs. Disease model (Ach-CaCl2 induced paroxysmal atrial fibrillation without antagonist) was evaluated on Atrial fibrillation susceptibility (induction latency and duration) and structural remodeling (p=<0.05). P2X7 receptor antagonism with A-438079 significantly reduced atrial fibrillation susceptibility and ameliorated structural and autonomic remodeling via the ROS-MAPK signaling axis in a rat model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: